Boston – June 1, 2016 – Cooley advised the underwriters on the $61.4 million initial public offering of Merus. The company now trades on the NASDAQ Global Market under the symbol "MRUS."
Citigroup Global Markets Inc. and Jefferies LLC acted as joint book-running managers for the offering. Guggenheim Securities acted as lead manager for the offering and Wedbush PacGrow acted as co-manager.
Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, referred to as Biclonics. Biclonics are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity.
The Cooley corporate and securities team advising the underwriters included Div Gupta, Marc Recht, Brian Leaf, Courtney Thorne and Esther Cho.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.